Healthcare

Moody's Investors Service warned of a possible downgrade of Abbott Laboratories on Wednesday, citing the drug and medical products company's bid to buy Facet Biotech for $450 million.

Moody's Investors Service warned of a possible downgrade of Abbott Laboratories on Wednesday, citing the drug and medical products company's bid to buy Facet Biotech for $450 million.

Moody's Investors Service warned of a possible downgrade of Abbott Laboratories on Wednesday, citing the drug and medical products company's bid to buy Facet Biotech for $450 million.

Moody's Investors Service warned of a possible downgrade of Abbott Laboratories on Wednesday, citing the drug and medical products company's bid to buy Facet Biotech for $450 million.